Pure Bioscience, Inc. (PURE) — SEC Filings
Pure Bioscience, Inc. (PURE) — 19 SEC filings. Latest: 8-K (May 5, 2026). Includes 8 8-K, 6 10-Q, 3 DEF 14A.
View Pure Bioscience, Inc. on SEC EDGAR
Overview
Pure Bioscience, Inc. (PURE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 30, 2025: PURE Bioscience, Inc. is holding its 2026 Annual Meeting of Stockholders on February 17, 2026, where key proposals include the election of seven directors, the ratification of Weinberg & Company, P.A. as the independent auditor for fiscal year ending July 31, 2026, and a non-binding advisory vote on
Sentiment Summary
Across 19 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 3 mixed. The dominant filing sentiment for Pure Bioscience, Inc. is neutral.
Filing Type Overview
Pure Bioscience, Inc. (PURE) has filed 8 8-K, 3 DEF 14A, 6 10-Q, 2 10-K with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (19)
Risk Profile
Risk Assessment: Of PURE's 18 recent filings, 3 were flagged as high-risk, 6 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Robert Bartlett
- Mr. Chen
- Mr. Rendall
- Mr. Blotner
- Mr. Zehr
- Chief Executive Officer
- President
- Michael L. Krall
- David L. Johnson
- Robert L. Smith
Industry Context
PURE Bioscience operates in the bioscience sector, which is characterized by innovation, significant research and development investment, and stringent regulatory oversight. The industry is competitive, with companies often focusing on specialized niches like antimicrobial solutions. Trends include increasing demand for effective and sustainable hygiene and disinfection technologies, driven by public health concerns and evolving industry standards.
Top Tags
SEC Filing (4) · 10-Q (4) · corporate-governance (3) · financials (3) · Proxy Statement (2) · Biotechnology (2) · Going Concern (2) · Small Cap (2) · quarterly-report (2) · shareholder-vote (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Date of Annual Meeting | 2026-02-17 | Scheduled date for PURE Bioscience's Annual Meeting of Stockholders |
| Record Date | 2025-12-22 | Date for determining stockholders entitled to vote at the Annual Meeting |
| Shares of Common Stock Outstanding | 111,886,485 | Number of shares issued and outstanding as of the Record Date |
| Current Authorized Common Stock | 200,000,000 | Current maximum number of shares PURE Bioscience is authorized to issue |
| Proposed Authorized Common Stock | 250,000,000 | New maximum number of shares PURE Bioscience proposes to be authorized to issue |
| Number of Directors | 7 | Number of directors to be elected at the Annual Meeting |
| Number of Independent Directors | 4 | Number of independent directors on PURE Bioscience's Board |
| Board Meetings | 6 | Number of times the Board met during the fiscal year ended July 31, 2025 |
| Audit Committee Meetings | 4 | Number of times the Audit Committee met during the fiscal year ended July 31, 2025 |
| Holders of Record | 220 | Number of stockholders of record as of December 22, 2025 |
| Net loss for Q1 2026 | $464,000 | Reduced from $689,000 in Q1 2025 |
| Total revenue for Q1 2026 | $708,000 | Increased 27.3% from $556,000 in Q1 2025 |
| Stockholders' deficiency as of October 31, 2025 | $5,546,000 | Indicates significant financial instability |
| Net cash used in operating activities for Q1 2026 | $250,000 | Highlights ongoing cash burn |
| Current convertible notes payable to related parties | $2,104,000 | Significant increase in short-term debt obligations |
Frequently Asked Questions
What are the latest SEC filings for Pure Bioscience, Inc. (PURE)?
Pure Bioscience, Inc. has 19 recent SEC filings from Jan 2024 to May 2026, including 8 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PURE filings?
Across 19 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Pure Bioscience, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pure Bioscience, Inc. (PURE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pure Bioscience, Inc.?
Key financial highlights from Pure Bioscience, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PURE?
The investment thesis for PURE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pure Bioscience, Inc.?
Key executives identified across Pure Bioscience, Inc.'s filings include Robert Bartlett, Mr. Chen, Mr. Rendall, Mr. Blotner, Mr. Zehr and 5 others.
What are the main risk factors for Pure Bioscience, Inc. stock?
Of PURE's 18 assessed filings, 3 were flagged high-risk, 6 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Pure Bioscience, Inc.?
Forward guidance and predictions for Pure Bioscience, Inc. are extracted from SEC filings as they are enriched.